К основному контенту

Millions of tons of nitrate from industrial farming find their way into America's drinking water

 Millions of tons of nitrate from industrial farming find their way into America's drinking water each year, causing thousands of cases of cancer and other health problems, an environmental advocacy group says.


In a new report, researchers from the Environmental Working Group (EWG) quantify the risk. They say nitrate is responsible for nearly 12,600 cases of cancer a year.

"Industrialized farming relies heavily on nitrate fertilizers that can run off into the water table used by drinking water utilities," said Sydney Evans, a science analyst at EWG.

The risk varies from region to region, she said, noting that many small farming communities have the highest nitrate levels in their water -- and the highest risk. Iowa and California, two heavily agricultural states, were found to have the most nitrate-related cancer cases.

A Yale University researcher who reviewed the report said the danger it highlights is clear and exists throughout the country.

"An immediate response is warranted, so that we are not poisoning our water to produce our food," said Dr. David Katz, director of the Yale-Griffin Prevention Research Center in New Haven, Conn.

The report said 80% of the nitrate-related cancers were colorectal, with ovarian, thyroid, kidney and bladder cancer accounting for the rest. Treatment costs up to $1.5 billion a year, according to the report.

Nitrate in tap water also has been tied to serious health issues for infants, the researchers said. Among them: nearly 3,000 babies with very low birth weight; more than 1,700 preterm births; and 41 cases of neural tube defects each year in the United States.

Katz said that although the study has limitations, it makes a compelling case that nitrates from what he described as "agriculture as usual" in the United States are "imposing grave costs measured in both lives and dollars."

Meanwhile, Evans called on the U.S. Environmental Protection Agency (EPA) to revisit its public health standards for drinking water. A main mission of her group is to prevent nitrate from fouling drinking water.

Since 1962, the federal standard for nitrate in drinking water has stood at 10 milligrams per liter. The report said problems have been found at one-tenth of that level.

The EPA was slated to re-evaluate its standards with an eye to reducing the permissible level in drinking water, but the Trump administration canceled those plans, Evans said.

For tap water to be safe, she said nitrate levels would have to be 70 times lower than today.

Nitrate is hard and costly to filter out of water, Evans said. Some towns and cities, however, do remove it and pass along the cost to residents.

Private wells can also have high nitrate levels. People who rely on well water have to spend thousands of dollars to add reverse osmosis systems if they want to remove nitrate, Evans said.

The best policy, she said, is to prevent large quantities of nitrate from getting into the water in the first place. It's up to the government to set safe standards and make sure the farm industry adheres to them, she added.

The report was published June 11 in the journal Environmental Research.

Комментарии

Популярные сообщения из этого блога

A healthy diet may trigger a better response to a certain kind of melanoma treatment. How?

New research suggests that a diet that's full of fiber appears to lead to more diverse intestinal bacteria (microbiome). In turn, a thriving gut microbiome is linked to a stronger response to an immune therapy for the aggressive skin cancer. "We found that patients eating a high-fiber diet at the start of therapy were about five times more likely to respond to the anti-PD-1 immunotherapy," said study author Christine Spencer. She's a research scientist with the Parker Institute for Cancer Immunotherapy in San Francisco. Anti-PD-1 immunotherapy helps the immune system recognize cancer cells as dangerous cells that need to be destroyed, according to the American Cancer Society (ACS). The cancer drugs Keytruda and Opdivo are examples of this type of immunotherapy. Melanoma is a type of skin cancer. It only accounts for about 1 percent of all skin cancers, but is responsible for most skin cancer deaths, the ACS says. Several recent studies have suggested that a ...

American Heart Association News

On Feb. 1, 1961, twins Debbie and Donna Horst arrived at the White House to fanfare. The 6-year-olds, decked out in fancy dresses and satin sashes, found themselves surrounded by a pressing crowd and a sea of blinding flashbulbs as they made their way to see Jacqueline Kennedy. The girls -- both born with holes in their aortas -- were meeting with the first lady to kick off a national campaign to raise awareness about congenital heart defects. "There were hundreds of reporters because this was Jacqueline Kennedy' first public act as first lady," Debbie said. She recalls being startled when the reporters asked Mrs. Kennedy if they could move in closer. "It was frightening because they all jumped at us at once." The Pennsylvania twins, just a few weeks from turning 7, were among the first "Heart Fund Sweethearts" in the campaign to raise money as well as awareness. The month before, they'd met up with Micki and Patricia Gane, also of Pennsylvania...

Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Low-Dose

Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Low-Dose Contraceptive Patch, Twirla PRINCETON, N.J., May 17, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it has resubmitted to the U.S. Food and Drug Administration (FDA) the NDA for its lead product candidate, Twirla®, an investigational low-dose combined hormonal contraceptive patch (AG200-15).  Agile resubmitted the NDA in response to a December 2017 Complete Response Letter (CRL) from the FDA, which identified deficiencies relating to (i) quality control adhesion test methods for the Twirla manufacturing process, (ii) observations identified during an inspection of a facility of our third-party manufacturer for the Twirla NDA that must be resolved, and (iii) questions on the in vivo adhesion properties of Twirla and their potential relationship to the SECURE clinical trial results. The resubmitted NDA includes the results from a...